Bigul

IPCA LABORATORIES LTD. - 524494 - Electronic Dispatch Of Postal Ballot Notice To Shareholders

We wish to inform you that the Company has on 27th February, 2023 completed the electronic dispatch of the Postal Ballot Notice under the provisions of Section 110 of the Companies Act, 2013, to the Members whose names appear in Register of Members/Beneficial owners as on the cut-off date i.e. 23rd February, 2023 seeking assent / dissent of the Members through Postal Ballot only through e-voting for the Special / Ordinary resolutions to be passed as per the postal ballot notice dated 14th February, 2023
27-02-2023
Bigul

IPCA LABORATORIES LTD. - 524494 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

We are enclosing herewith Postal Ballot Notice seeking the approval of the members of the Company on items of the following Special / Ordinary Businesses as set out in the attached Postal Ballot Notice dt. 14th February, 2023.
24-02-2023

Ipca Laboratories Results Earnings Call for Q3FY23

Conference Call with Ipca Laboratories Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
20-02-2023
Bigul

IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

We are enclosing herewith transcript of our Conference Call which was held on Thursday, 16th February, 2023 to discuss the Company's Q3FY23 earnings and business update.
20-02-2023

Hold Ipca Laboratories; target of Rs 909: Sharekhan

Sharekhan recommended Hold rating on Ipca Laboratories with a target price of Rs 909 in its research report dated February 17, 2023.
18-02-2023
Bigul

IPCA LABORATORIES LTD. - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication

We are enclosing herewith copies of the Unaudited Financial Results for the 3rd quarter and nine months ended 30th December, 2022 published in Free Press Journal, Financial Express and Nav Shakti on 15th February, 2023.
15-02-2023
Bigul

Q3FY23 Quarterly Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals firm Ipca Laboratories announced Q3FY23 results: Q3FY23: Standalone net total Income up 9% at Rs1,458.09 crore Consolidated net total Income up 9% at Rs 1,576.89 crore Indian formulations income up 9% at Rs 702.25 crore Exports income up 12% at Rs 637.66 crore Standalone EBITDA margin (before forex (gain)/loss) at 17.51% in Q3FY23 as against 23.49% in Q3FY22 Consolidated EBITDA margin at 16.67% in Q3FY23 as against 21.53% in Q3FY22 Standalone net profit at Rs 120.27 crore down 45% Consolidated net profit at Rs 107.84 crore, down 45% 9MFY23: Standalone net total income up 5% at Rs 4,467.65 crore Consolidated net total income up 5% at Rs 4,821.92 crore Indian formulations income up 10% at Rs 2,152.77 crore Exports income down 1% at Rs 1,953.97 crore Standalone EBITDA margin (before forex (gain) /loss) at 19.38% in 9MFY23 as against 25.13% in 9MFY22 Consolidated EBITDA margin at 18.18% in 9MFY23 as against 24.15% in 9MFY22 Standalone net profit at Rs 431.87 crore, down 43% Consolidated net profit at Rs 394.80 crore, down 48% Result PDF
14-02-2023
Bigul

IPCA LABORATORIES LTD. - 524494 - Standalone And Consolidated Unaudited Financial Results Along With Limited Review Reports Of The Company'S Statutory Auditors Thereon For The 3Rd Quarter And Nine Months Ended 31St December, 2022, Which Was Taken On Record At The Meeting Of The Board Of Directors Of The Company Held Today At Mumbai.

Standalone and Consolidated Unaudited Financial Results along with limited review reports of the Company's Statutory Auditors thereon for the 3rd Quarter and nine months ended 31st December, 2022, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.
14-02-2023
Next Page
Close

Let's Open Free Demat Account